Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1985 1
1986 1
1987 1
1989 1
1990 2
1991 3
1992 6
1993 20
1994 18
1995 29
1996 32
1997 36
1998 39
1999 68
2000 56
2001 69
2002 70
2003 108
2004 124
2005 173
2006 137
2007 192
2008 157
2009 116
2010 104
2011 78
2012 59
2013 38
2014 38
2015 31
2016 19
2017 12
2018 16
2019 9
2020 12
2021 12
2022 6
2023 5
2024 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,802 results

Results by year

Filters applied: . Clear all
Page 1
Hormone-refractory Prostate Cancer.
Rini BI, Small EJ. Rini BI, et al. Curr Treat Options Oncol. 2002 Oct;3(5):437-46. doi: 10.1007/s11864-002-0008-1. Curr Treat Options Oncol. 2002. PMID: 12194808 Review.
However, all patients treated with androgen deprivation eventually develop resistant disease as manifested by increasing prostate-specific antigen levels, progressive disease on imaging studies, and ultimately worsening symptoms. The treatment of patients with hormone-r …
However, all patients treated with androgen deprivation eventually develop resistant disease as manifested by increasing prostate-specific a …
[Hormone-refractory prostate cancer].
Alexandre I, Rixe O. Alexandre I, et al. Ann Urol (Paris). 2007 Apr;41(2):47-55. doi: 10.1016/j.anuro.2007.02.003. Ann Urol (Paris). 2007. PMID: 17486912 Review. French.
Hormone-refractory prostate cancer is an advanced stage of the metastatic disease; it has a poor prognosis and a short median survival, about 9 to 18 months. ...
Hormone-refractory prostate cancer is an advanced stage of the metastatic disease; it has a poor prognosis and a …
Update on hormone-refractory prostate cancer.
Kasamon KM, Dawson NA. Kasamon KM, et al. Curr Opin Urol. 2004 May;14(3):185-93. doi: 10.1097/00042307-200405000-00008. Curr Opin Urol. 2004. PMID: 15069310 Review.
Unfortunately, androgen deprivation therapy is primarily palliative, with nearly all men progressing to an androgen-independent state. Hormone-refractory prostate cancer presents significant management challenges and is the focus of this review. RECENT …
Unfortunately, androgen deprivation therapy is primarily palliative, with nearly all men progressing to an androgen-independent state. Ho …
Hormone refractory prostate cancer.
Crawford ED, Rosenblum M, Ziada AM, Lange PH. Crawford ED, et al. Urology. 1999 Dec;54(6A Suppl):1-7. doi: 10.1016/s0090-4295(99)00447-1. Urology. 1999. PMID: 10606277 Review. No abstract available.
Hormone-refractory prostate cancer in the Lobund-Wistar rat.
Pollard M, Suckow MA. Pollard M, et al. Exp Biol Med (Maywood). 2005 Sep;230(8):520-6. doi: 10.1177/153537020523000802. Exp Biol Med (Maywood). 2005. PMID: 16118401 Free article. Review.
There is a great need for an animal model of prostate cancer (PC), one that develops cancer from initial premalignant to the terminal refractory stages. We describe here a model of hormone-refractory prostate cancer (HRPC) that develops spontaneously t …
There is a great need for an animal model of prostate cancer (PC), one that develops cancer from initial premalignant to the terminal refrac …
Chemotherapy in hormone-refractory prostate cancer.
de Wit R. de Wit R. BJU Int. 2008 Mar;101 Suppl 2:11-5. doi: 10.1111/j.1464-410X.2007.07485.x. BJU Int. 2008. PMID: 18307687 Review.
The results of the TAX 327 and SWOG 99-16 trials for the first time showed an improvement in overall survival (OS) with docetaxel-based chemotherapy in patients with metastatic hormone-refractory prostate cancer. As such, 3-weekly (q3w) docetaxel plus …
The results of the TAX 327 and SWOG 99-16 trials for the first time showed an improvement in overall survival (OS) with docetaxel-based chem …
Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H, Hu L. Aloysius H, et al. Med Res Rev. 2015 May;35(3):554-85. doi: 10.1002/med.21333. Epub 2014 Dec 22. Med Res Rev. 2015. PMID: 25529338 Review.
Due to the propensity of relapse and resistance with prolonged androgen deprivation therapy (ADT), there is a growing interest in developing non-hormonal therapeutic approaches as alternative treatment modalities for hormone refractory prostate cancer …
Due to the propensity of relapse and resistance with prolonged androgen deprivation therapy (ADT), there is a growing interest in developing …
[Treatment options for hormone-refractory prostate cancer].
Heidenreich A, Ohlmann CH. Heidenreich A, et al. Urologe A. 2005 Nov;44(11):1303-4, 1306-14. doi: 10.1007/s00120-005-0928-z. Urologe A. 2005. PMID: 16237541 Review. German.
However, about 90% of the men treated will develop PSA progression within 3-4 years resulting in androgen-independent and later on hormone-refractory prostate cancer. Management of AIPCA and HRPCA still represents a therapeutic challenge despite the de …
However, about 90% of the men treated will develop PSA progression within 3-4 years resulting in androgen-independent and later on hormon …
Hormone-refractory prostate cancer: a shifting paradigm in treatment.
Gallagher E, Gapstur R. Gallagher E, et al. Clin J Oncol Nurs. 2006 Apr;10(2):233-40. doi: 10.1188/06.CJON.233-240. Clin J Oncol Nurs. 2006. PMID: 16708706 Review.
However, for the first time, docetaxel-based regimens have demonstrated improved survival in men with hormone-refractory prostate cancer in two different, large, phase III studies. Additionally, a number of novel agents are being developed with the hop …
However, for the first time, docetaxel-based regimens have demonstrated improved survival in men with hormone-refractory pr …
Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F, Karapanagiotou EM, Syrigos KN. Stavridi F, et al. Cancer Treat Rev. 2010 Apr;36(2):122-30. doi: 10.1016/j.ctrv.2009.06.001. Epub 2010 Jan 27. Cancer Treat Rev. 2010. PMID: 20106600 Review.
Docetaxel represents the first chemotherapeutic agent with a small survival benefit for metastatic hormone-refractory prostate cancer (HRPC). In an attempt to improve survival benefit, several novel drugs targeting specific pathways involved in cell si …
Docetaxel represents the first chemotherapeutic agent with a small survival benefit for metastatic hormone-refractory prost …
1,802 results